dbGaP

Subject ID, affection status, family number, individual is known to harbor a LRRK2 mutation, source of DNA, clean dataset used to create marker QC filter thresholds, clean dataset used to perform \"pre-computes\" of association analyses, the main cluster derived from the first two components of the multidimensional scaling algorithm, call rate below 96%, poor data quality for copy number variant data, XO (only one X chromosome and no Y chromosome observed) or XO mosaic - possible Turner syndrome, probable artifact of the cell line, age of onset of Parkinson disease symptoms, year of birth, year of study visit, gender, race, ethnicity, family history of Parkinson disease, participant history of traumatic brain injury, of strokes, of encephalitis, oculogyric crisis, of suggesting Alzheimer disease or other dementing illness, asymmetric onset of disease symptoms, bradykinesia, resting tremor, rigidity, postural instability, gait dysfunction, sustained remission of parkinsonian symptoms, supranuclear gaze palsy with downgaze less than 50% of normal, cerebellar signs, Hoehn and Yahr stage, Unified Parkinson's Disease Rating Scale II, Unified Parkinson's Disease Rating Scale III, Mini-Mental Status Exam total score, smoking status, and marked response to levodopa therapy of participants with Parkinson disease and involved in the \"CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)\" project.

Subject ID, affection status, family number, individual is known to harbor a LRRK2 mutation, source of DNA, clean dataset used to create marker QC filter thresholds, clean dataset used to perform \"pre-computes\" of association analyses, the main cluster derived from the first two components of the multidimensional scaling algorithm, call rate below 96%, poor data quality for copy number variant data, XO (only one X chromosome and no Y chromosome observed) or XO mosaic - possible Turner syndrome, probable artifact of the cell line, age of onset of Parkinson disease symptoms, year of birth, year of study visit, gender, race, ethnicity, family history of Parkinson disease, participant history of traumatic brain injury, of strokes, of encephalitis, oculogyric crisis, of suggesting Alzheimer disease or other dementing illness, asymmetric onset of disease symptoms, bradykinesia, resting tremor, rigidity, postural instability, gait dysfunction, sustained remission of parkinsonian symptoms, supranuclear gaze palsy with downgaze less than 50% of normal, cerebellar signs, Hoehn and Yahr stage, Unified Parkinson's Disease Rating Scale II, Unified Parkinson's Disease Rating Scale III, Mini-Mental Status Exam total score, smoking status, and marked response to levodopa therapy of participants with Parkinson disease and involved in the \"CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)\" project.

Subject ID, affection status, family number, individual is known to harbor a LRRK2 mutation, source of DNA, clean dataset used to create marker QC filter thresholds, clean dataset used to perform \"pre-computes\" of association analyses, the main cluster derived from the first two components of the multidimensional scaling algorithm, call rate below 96%, poor data quality for copy number variant data, XO (only one X chromosome and no Y chromosome observed) or XO mosaic - possible Turner syndrome, probable artifact of the cell line, age of onset of Parkinson disease symptoms, year of birth, year of study visit, gender, race, ethnicity, family history of Parkinson disease, participant history of traumatic brain injury, of strokes, of encephalitis, oculogyric crisis, of suggesting Alzheimer disease or other dementing illness, asymmetric onset of disease symptoms, bradykinesia, resting tremor, rigidity, postural instability, gait dysfunction, sustained remission of parkinsonian symptoms, supranuclear gaze palsy with downgaze less than 50% of normal, cerebellar signs, Hoehn and Yahr stage, Unified Parkinson's Disease Rating Scale II, Unified Parkinson's Disease Rating Scale III, Mini-Mental Status Exam total score, smoking status, and marked response to levodopa therapy of participants with Parkinson disease and involved in the \"CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)\" project.

Subject ID, affection status, family number, individual is known to harbor a LRRK2 mutation, source of DNA, clean dataset used to create marker QC filter thresholds, clean dataset used to perform \"pre-computes\" of association analyses, the main cluster derived from the first two components of the multidimensional scaling algorithm, call rate below 96%, poor data quality for copy number variant data, XO (only one X chromosome and no Y chromosome observed) or XO mosaic - possible Turner syndrome, probable artifact of the cell line, age of onset of Parkinson disease symptoms, year of birth, year of study visit, gender, race, ethnicity, family history of Parkinson disease, participant history of traumatic brain injury, of strokes, of encephalitis, oculogyric crisis, of suggesting Alzheimer disease or other dementing illness, asymmetric onset of disease symptoms, bradykinesia, resting tremor, rigidity, postural instability, gait dysfunction, sustained remission of parkinsonian symptoms, supranuclear gaze palsy with downgaze less than 50% of normal, cerebellar signs, Hoehn and Yahr stage, Unified Parkinson's Disease Rating Scale II, Unified Parkinson's Disease Rating Scale III, Mini-Mental Status Exam total score, smoking status, and marked response to levodopa therapy of participants with Parkinson disease and involved in the \"CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)\" project.

Subject ID, family number, type of control, source of DNA, clean dataset used to create marker QC filter thresholds, clean dataset used to perform \"pre-computes\" of association analyses, the main cluster derived from the first two components of the multidimensional scaling algorithm, call rate below 96%, poor data quality for copy number variant data, XO (only one X chromosome and no Y chromosome observed) or XO mosaic - possible Turner syndrome, probable artifact of the cell line, age at enrollment, gender, race, ethnicity, subject's country of birth, family history of amyotrophic lateral sclerosis, of ataxia, of autism, of bipolar disorder, of brain aneurysm, of cancer, of dementia, of depression, of diabetes, of dystonia, of epilepsy, of heart disease, of hypertension, of memory loss, of migraine, of migraine, of muscle disease, of obsessive compulsive disorder, of other known medical illnesses, of Parkinson disease, of schizophrenia, of cerebrovascular disease, of suicide attempt, of Tourette's syndrome, participant history of amyotrophic lateral sclerosis, of ataxia, of autism, of bipolar disorder, brain aneurysm, of cancer, of dementia, of depression, of diabetes, of dystonia, of epilepsy, of heart disease, of hypertension, of memory loss, of migraine, of multiple scleroses, muscle disease, obsessive compulsive disorder, of other medical illnesses, of Parkinson disease, of schizophrenia, of cerebrovascular disease, of a past suicide attempt, of Tourette's syndrome, Mini Mental Status Score, subject hand preference, subject either did (yes) or did not (no) undergo a neurological examination, and smoking status of participants without Parkinson disease and involved in the \"CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)\" project.

Subject ID, family number, type of control, source of DNA, clean dataset used to create marker QC filter thresholds, clean dataset used to perform \"pre-computes\" of association analyses, the main cluster derived from the first two components of the multidimensional scaling algorithm, call rate below 96%, poor data quality for copy number variant data, XO (only one X chromosome and no Y chromosome observed) or XO mosaic - possible Turner syndrome, probable artifact of the cell line, age at enrollment, gender, race, ethnicity, subject's country of birth, family history of amyotrophic lateral sclerosis, of ataxia, of autism, of bipolar disorder, of brain aneurysm, of cancer, of dementia, of depression, of diabetes, of dystonia, of epilepsy, of heart disease, of hypertension, of memory loss, of migraine, of migraine, of muscle disease, of obsessive compulsive disorder, of other known medical illnesses, of Parkinson disease, of schizophrenia, of cerebrovascular disease, of suicide attempt, of Tourette's syndrome, participant history of amyotrophic lateral sclerosis, of ataxia, of autism, of bipolar disorder, brain aneurysm, of cancer, of dementia, of depression, of diabetes, of dystonia, of epilepsy, of heart disease, of hypertension, of memory loss, of migraine, of multiple scleroses, muscle disease, obsessive compulsive disorder, of other medical illnesses, of Parkinson disease, of schizophrenia, of cerebrovascular disease, of a past suicide attempt, of Tourette's syndrome, Mini Mental Status Score, subject hand preference, subject either did (yes) or did not (no) undergo a neurological examination, and smoking status of participants without Parkinson disease and involved in the \"CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)\" project.

Subject ID, subject source, source subject ID, consent group, and affection status of participants with or without Parkinson disease and involved in the \"CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)\" project.

Subject ID, family number, type of control, source of DNA, clean dataset used to create marker QC filter thresholds, clean dataset used to perform \"pre-computes\" of association analyses, the main cluster derived from the first two components of the multidimensional scaling algorithm, call rate below 96%, poor data quality for copy number variant data, XO (only one X chromosome and no Y chromosome observed) or XO mosaic - possible Turner syndrome, probable artifact of the cell line, age at enrollment, gender, race, ethnicity, subject's country of birth, family history of amyotrophic lateral sclerosis, of ataxia, of autism, of bipolar disorder, of brain aneurysm, of cancer, of dementia, of depression, of diabetes, of dystonia, of epilepsy, of heart disease, of hypertension, of memory loss, of migraine, of migraine, of muscle disease, of obsessive compulsive disorder, of other known medical illnesses, of Parkinson disease, of schizophrenia, of cerebrovascular disease, of suicide attempt, of Tourette's syndrome, participant history of amyotrophic lateral sclerosis, of ataxia, of autism, of bipolar disorder, brain aneurysm, of cancer, of dementia, of depression, of diabetes, of dystonia, of epilepsy, of heart disease, of hypertension, of memory loss, of migraine, of multiple scleroses, muscle disease, obsessive compulsive disorder, of other medical illnesses, of Parkinson disease, of schizophrenia, of cerebrovascular disease, of a past suicide attempt, of Tourette's syndrome, Mini Mental Status Score, subject hand preference, subject either did (yes) or did not (no) undergo a neurological examination, and smoking status of participants without Parkinson disease and involved in the \"CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)\" project.

Subject ID, family number, type of control, source of DNA, clean dataset used to create marker QC filter thresholds, clean dataset used to perform \"pre-computes\" of association analyses, the main cluster derived from the first two components of the multidimensional scaling algorithm, call rate below 96%, poor data quality for copy number variant data, XO (only one X chromosome and no Y chromosome observed) or XO mosaic - possible Turner syndrome, probable artifact of the cell line, age at enrollment, gender, race, ethnicity, subject's country of birth, family history of amyotrophic lateral sclerosis, of ataxia, of autism, of bipolar disorder, of brain aneurysm, of cancer, of dementia, of depression, of diabetes, of dystonia, of epilepsy, of heart disease, of hypertension, of memory loss, of migraine, of migraine, of muscle disease, of obsessive compulsive disorder, of other known medical illnesses, of Parkinson disease, of schizophrenia, of cerebrovascular disease, of suicide attempt, of Tourette's syndrome, participant history of amyotrophic lateral sclerosis, of ataxia, of autism, of bipolar disorder, brain aneurysm, of cancer, of dementia, of depression, of diabetes, of dystonia, of epilepsy, of heart disease, of hypertension, of memory loss, of migraine, of multiple scleroses, muscle disease, obsessive compulsive disorder, of other medical illnesses, of Parkinson disease, of schizophrenia, of cerebrovascular disease, of a past suicide attempt, of Tourette's syndrome, Mini Mental Status Score, subject hand preference, subject either did (yes) or did not (no) undergo a neurological examination, and smoking status of participants without Parkinson disease and involved in the \"CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)\" project.

Subject ID, family number, type of control, source of DNA, clean dataset used to create marker QC filter thresholds, clean dataset used to perform \"pre-computes\" of association analyses, the main cluster derived from the first two components of the multidimensional scaling algorithm, call rate below 96%, poor data quality for copy number variant data, XO (only one X chromosome and no Y chromosome observed) or XO mosaic - possible Turner syndrome, probable artifact of the cell line, age at enrollment, gender, race, ethnicity, subject's country of birth, family history of amyotrophic lateral sclerosis, of ataxia, of autism, of bipolar disorder, of brain aneurysm, of cancer, of dementia, of depression, of diabetes, of dystonia, of epilepsy, of heart disease, of hypertension, of memory loss, of migraine, of migraine, of muscle disease, of obsessive compulsive disorder, of other known medical illnesses, of Parkinson disease, of schizophrenia, of cerebrovascular disease, of suicide attempt, of Tourette's syndrome, participant history of amyotrophic lateral sclerosis, of ataxia, of autism, of bipolar disorder, brain aneurysm, of cancer, of dementia, of depression, of diabetes, of dystonia, of epilepsy, of heart disease, of hypertension, of memory loss, of migraine, of multiple scleroses, muscle disease, obsessive compulsive disorder, of other medical illnesses, of Parkinson disease, of schizophrenia, of cerebrovascular disease, of a past suicide attempt, of Tourette's syndrome, Mini Mental Status Score, subject hand preference, subject either did (yes) or did not (no) undergo a neurological examination, and smoking status of participants without Parkinson disease and involved in the \"CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)\" project.